57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]
Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]
Undetectable Viral Load Sustained Over 20 Weeks in SB-728-902 Study; Data Demonstrate Dose Response in SB-728-1101 Cytoxan Study; Reduction of Viral Reservoir Observed in All Immune Non-Responders Over Three Years RICHMOND, Calif., Dec. 6, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from all dose cohorts in the Company’s ongoing clinical trials (SB-728-1101 […]
– Sovaldi Approved for Use in Genotypes 1, 2, 3 or 4 – – High Cure Rates (SVR12) and Shortened, 12-Week Course of Therapy for Many Patients – – First Ever Oral Treatment Regimen for Genotypes 2 or 3 – – First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence – FOSTER CITY, […]
– Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal – PARIS, Dec. 5, 2013 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia® (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast […]
INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the […]
PITTSBURGH, Dec. 5, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration […]
Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions Mylan Board of Directors Sets April 11, 2014 as Date for Annual Meeting of Shareholders PITTSBURGH, Dec. 4, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides […]
– New, Interim Phase 3 Data Highlight Prolonged Half-Life of ELOCTATE™ and ALPROLIX™ in Young Children – – 10 Abstracts, Including Oral Presentation, Highlight Data from Hemophilia Research and Development Program – CAMBRIDGE, Mass.–(December 3, 2013)–Biogen Idec (NASDAQ: BIIB) will present new data from its hemophilia clinical development and research programs at the 55th Annual Meeting of the […]
A broad range of components for dose-efficient imaging systems, image processing workstations, and cancer treatment technologies, are on display at RSNA in Chicago CHICAGO, Dec. 2, 2013 /PRNewswire/ — Booth 4304 — A new lightweight wireless flat-panel digital X-ray image detector ideal for imaging extremities and for use in neonatal imaging systems is among the imaging components that […]